title: A new era in the treatment of melanoma: from biology to clinical practice.
abstract: Melanoma is the deadliest cutaneous malignancy and its incidence continues to grow. Until 2011, the treatment options for metastatic melanoma were scarce and without any overall survival benefit. The emergence of new targeted therapies for BRAF mutant melanoma (vemurafenib) and immunotherapy (ipilimumab) has changed the standard of care for this disease. The objective of the present review is to summarise the biological background of the new therapeutic approaches in melanoma, focusing on apoptosis resistance, immune modulation and angiogenesis, and the direct translation into clinical practice.
authors.affiliation: Servicio de Oncología Médica, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain. ivanpantic@hotmail.com
authors.forename: I
authors.initials: I
authors.lastname: Márquez-Rodas
authors.forename: S
authors.initials: S
authors.lastname: Martín Algarra
authors.forename: J A
authors.initials: JA
authors.lastname: Avilés Izquierdo
authors.forename: S
authors.initials: S
authors.lastname: Custodio Cabello
authors.forename: M
authors.initials: M
authors.lastname: Martín
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis; D014408:Biomarkers, Tumor / Q000378:metabolism; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008545:Melanoma / Q000276:immunology / Q000378:metabolism / Q000628:therapy*; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics; D012878:Skin Neoplasms / Q000276:immunology / Q000378:metabolism / Q000628:therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf
references.citation: Oncogene. 2003 May 19;22(20):3138-51
references.pmid: 12789290
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: N Engl J Med. 2011 Jun 30;364(26):2507-16
references.pmid: 21639808
references.citation: J Invest Dermatol. 2006 Jan;126(1):154-60
references.pmid: 16417231
references.citation: Surg Oncol Clin N Am. 2011 Jan;20(1):1-17
references.pmid: 21111956
references.citation: Int J Oncol. 2009 Jun;34(6):1481-9
references.pmid: 19424565
references.citation: Ther Adv Med Oncol. 2010 Nov;2(6):367-80
references.pmid: 21789148
references.citation: Semin Immunopathol. 2011 Jul;33(4):385-91
references.pmid: 21279809
references.citation: J Natl Cancer Inst. 2009 Jun 16;101(12):869-77
references.pmid: 19509353
references.citation: Ann Oncol. 2009 Aug;20 Suppl 6:vi1-7
references.pmid: 19617292
references.citation: J Clin Oncol. 2008 Jul 10;26(20):3445-55
references.pmid: 18612161
references.citation: Surg Today. 2010 Jun;40(6):494-500
references.pmid: 20496129
references.citation: Int J Immunopathol Pharmacol. 2008 Jul-Sep;21(3):493-500
references.pmid: 18831916
references.citation: Clin Cancer Res. 2008 Nov 1;14(21):6821-8
references.pmid: 18980976
references.citation: N Engl J Med. 2006 Feb 16;354(7):709-18
references.pmid: 16481638
references.citation: Mayo Clin Proc. 2008 Jul;83(7):825-46
references.pmid: 18613999
references.citation: Semin Oncol. 2007 Dec;34(6):555-65
references.pmid: 18083379
references.citation: N Engl J Med. 2010 Aug 26;363(9):809-19
references.pmid: 20818844
references.citation: J Exp Clin Cancer Res. 2000 Mar;19(1):21-34
references.pmid: 10840932
references.citation: N Engl J Med. 2010 Aug 19;363(8):711-23
references.pmid: 20525992
references.citation: J Clin Oncol. 2010 May 10;28(14):2460-6
references.pmid: 20385998
references.citation: Lancet. 2008 Jul 12;372(9633):117-26
references.pmid: 18620949
references.citation: Clin Cancer Res. 2010 Dec 1;16(23):5862-72
references.pmid: 21030496
references.citation: J Clin Invest. 2007 Jun;117(6):1466-76
references.pmid: 17549249
references.citation: Br J Cancer. 2008 Sep 2;99(5):734-40
references.pmid: 18728664
references.citation: Cancer. 2006 Apr 1;106(7):1431-42
references.pmid: 16511841
references.citation: Nature. 2002 Jun 27;417(6892):949-54
references.pmid: 12068308
references.citation: Cancer Immun. 2008 Jan 17;8:1
references.pmid: 18198818
references.citation: Cancer Res. 2001 Oct 1;61(19):7282-90
references.pmid: 11585767
references.citation: J Clin Oncol. 2011 Jul 20;29(21):2904-9
references.pmid: 21690468
references.citation: Clin Cancer Res. 2008 Jan 15;14(2):342-6
references.pmid: 18223206
references.citation: Cancer Res. 2010 Jul 1;70(13):5213-9
references.pmid: 20551059
references.citation: Cancer. 2010 Sep 1;116(17):4122-9
references.pmid: 20564157
references.citation: Biochem Biophys Res Commun. 1993 Feb 15;190(3):702-8
references.pmid: 8439321
references.citation: N Engl J Med. 2011 Jun 30;364(26):2517-26
references.pmid: 21639810
references.citation: Melanoma Res. 2010 Aug;20(4):318-25
references.pmid: 20375744
references.citation: Curr Opin Oncol. 2010 May;22(3):178-83
references.pmid: 20401974
references.citation: J Clin Oncol. 2008 Apr 20;26(12):2046-51
references.pmid: 18421059
references.citation: Cancer. 2009 Jan 1;115(1):119-27
references.pmid: 19090009
references.citation: Ann Oncol. 2009 Aug;20 Suppl 6:vi41-50
references.pmid: 19617297
references.citation: Melanoma Res. 2009 Oct;19(5):275-82
references.pmid: 19633580
references.citation: Nat Rev Clin Oncol. 2011 May 24;8(7):426-33
references.pmid: 21606968